Inovio Pharmaceuticals (INO)
(Delayed Data from NSDQ)
$11.13 USD
+0.07 (0.63%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $11.14 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
Inovio Pharmaceuticals, Inc. [INO]
Reports for Purchase
Showing records 261 - 280 ( 364 total )
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Second Zika Vaccine Human Trial Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q16 Financial Results; VGX-3100 Pivotal Trial Dosing Start in 4Q16; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Zika Virus Vaccine to Enter Human Trial Near Term; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q 2016 Results Reported: VGX-3100 Progressing Towards Phase 3 Initiation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive dMAb and DNA Vaccine Progress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.